NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Sharply different reactions to JAMA psychiatry & pharma commentary

The Journal of the American Medical Association this week published a commentary, “Psychiatrists’ Relationships With Pharmaceutical Companies: Part of the Problem or Part of the Solution?” by the chief of the National Institute of Mental Health.

On his blog, psychiatrist Daniel Carlat praises the “power (and courage) of the country’s chief psychiatrist calling his own profession out on the carpet for bad behavior.”

But on the Health Care Renewal blog, Dr. Bernard Carroll, past chair of the Duke psychiatry department, writes:

“With ludicrous optimism and a series of straw man discussions, Dr. Insel (NIMH chief) makes the case that things are not really as bad as they seemed to be or, if they were, then other specialty physicians were doing much the same things. Dr. Insel needs to recalibrate his ethical compass.

Why is an NIH Institute Director issuing this apologia for the corruption of academic psychiatry? Does he not have better things to do, such as ensuring that longstanding NIH regulations on conflict of interest are enforced?”

Read the entire blog posts cited above to get a fuller flavor of the dispute.

You might also like

Comments (4)

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Marilyn Mann

March 25, 2010 at 3:08 pm

Howard Brody also commented on this:
http://brodyhooked.blogspot.com/2010/03/nimh-director-on-industry-influence.html

sadnessaddiction

March 26, 2010 at 2:17 pm

Pristiq’s advertising is directly targeted at manipulating normal healthy women to want to be medicated. Women must stand up to big pharma’s bullying them to over-medicate with antidepressants washing out their emotions & personalities and interfering being mothers, sisters, brothers, daughters, partners and lovers.. Women are targeted for antidepressants by big Pharma in the same way that tobacco companies targeted us 70 years ago. Drug companies are so effective at selling unhappiness to women that women take more than twice as many antidepressants as men.Like effexor Wyeth/Pfizer plans on using modern marketing techniques and direct payments to doctors to have Pristiq over prescribed instead of used based on evidence based diagnosis. http://sadnessaddiction.blogspot.com/